2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2838-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von DOMENICA RUBINO und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: The benefits of oral semaglutide (sema) in people with overweight/obesity class I are understudied. This post hoc analysis of the OASIS 4 trial assessed the effect of oral sema on cardiometabolic outcomes by baseline BMI class.
Methods
Participants (pts) in OASIS 4 randomized to receive oral sema 25mg for 64 weeks were grouped by baseline BMI. Changes from baseline in body weight and biomarkers were compared in overweight/obesity class I (BMI 27-<35) vs obesity class II/III (BMI ≥35) cohorts.
Results
Pts with overweight/obesity class I (n=85) achieved similar changes in body weight vs those in obesity classes II/III (n=119; Table). A comparable proportion of pts shifted to lower BMI classes by week 64. At baseline, no pts were in the National Institute for Health and Care Excellence low health risk category based on waist to height ratio and 100% of the obesity class II/III cohort was considered high risk. By week 64, 23% of the overweight/obesity class I cohort shifted to low risk and 30% of the obesity class II/III cohort to low or increased risk. Changes from baseline in most clinical biomarkers were numerically greater in the overweight/obesity class I vs the obesity class II/III cohort.
Conclusion
Pts with overweight/obesity class I treated with oral sema had similar or greater improvements in cardiometabolic outcomes vs the obesity class II/III cohort. Sema initiation at lower baseline BMI may prevent the development or worsening of obesity-related complications. Disclosure D. Rubino: Other - Advisory panel, research support, shareholder; Current; AbbVie Inc. Other - steering committee, research support; Current; Amgen Inc. Other - advisory panel, steering committee, research support; Current; AstraZeneca. Other - advisory panel, research support; Current; Boehringer Ingelheim International GmbH. Other - advisory panel, speaker, research support,; Current; Novo Nordisk. Consultant; Current; Lilly, Shionogi & Co., Ltd. Advisory Panel; Current; Neurocrine Biosciences, Inc., Regeneron Pharmaceuticals Inc. Consultant; Current; Pfizer Inc., Roche Pharmaceuticals, Cytoki. Other - advisory, research support; Current; Terns Pharmaceutical. Advisory Panel; Current; Neuraly Inc. Consultant; Current; Ferring Pharmaceuticals. Consultant; Ended; NodThera. L. Wilson: Employee; Current; Novo Nordisk. A. Traina: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. N. Rathor: None. J. Wang: None. M. Knight: Consultant; Current; Novo Nordisk, Boehringer Ingelheim International GmbH. Consultant; Ended; Currax Pharmaceuticals.
Zitieren
APA
RUBINO, D., WILSON, L., TRAINA, A., RATHOR, N., WANG, J., & KNIGHT, M. (2026). 2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2838-lb
Vancouver
RUBINO D, WILSON L, TRAINA A, RATHOR N, WANG J, KNIGHT M. 2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2838-lb
BibTeX
@article{RUBINO2026,
author = {RUBINO, DOMENICA and WILSON, LAUREN and TRAINA, ANDREA and RATHOR, NAVEEN and WANG, JULIA and KNIGHT, MICHAEL},
title = {2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2838-lb}
}
EUVIMED